Compare 8x8 Inc (EGHT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $290.32M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 3.4× 8x8 Inc's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EGHT | MRVI | |
|---|---|---|
Market Cap | $290.32M | $977.37M |
Volume | 1,226,387 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $2.76 | $9.00 |
52-Week Low | $1.59 | $2.83 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $557.24M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% with a bullish technical signal despite bearish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
EGHT presents a high-risk, high-reward opportunity with substantial upside to analyst targets but faces execution risks amid negative earnings. The stock's low price-to-sales ratio of 0.39 suggests undervaluation, though high debt levels and thin margins require careful monitoring. Positive momentum in AI adoption and client acquisitions could drive revaluation if profitability targets are met.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
